Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Initiation of first of two expanded phase II trials of GVAX lung cancer vaccine

April 3, 2003

Pharmexa applies to begin phase I trial of HER-2 Protein AutoVac product

April 2, 2003

MediGene discontinues development of CVLP tumor vaccine

March 28, 2003

Protein Design Labs licenses SMART M195 antibody to Actinium

March 20, 2003

H3 Pharma licenses SC-1 from OncoMab

March 19, 2003

WX-G250 + low-dose IL-2 safe and active in progressive, metastatic RCC

March 18, 2003

GVAX enhances antitumor immunity in certain patients with advanced NSCLC

March 7, 2003

Aphton presents phase III results for G17DT to foreign regulatory authority

March 7, 2003

Aldara shows benefit in pivotal studies in actinic keratosis and basal cell carcinoma

March 5, 2003

Preliminary results from CpG-7909 proof-of-principle study announced

March 4, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...